- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | H.C. Wainwright bestätigt Kaufempfehlung für Gain Therapeutics Aktie | 14 | Investing.com Deutsch | ||
| 31.08. | H.C. Wainwright reiterates Gain Therapeutics stock rating at buy | 1 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics GAAP EPS of -$0.11 beats by $0.03 | 5 | Seeking Alpha | ||
| 11.08. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update | 554 | GlobeNewswire (Europe) | BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 16.07. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.07. | Gain Therapeutics plans phase 2 Parkinson's study in Q3 2026 | 1 | Investing.com | ||
| 16.07. | Gain Therapeutics plant Phase-2-Studie zu Parkinson für drittes Quartal 2026 | 1 | Investing.com Deutsch | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update | 391 | GlobeNewswire (Europe) | BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 01.07. | H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval | 3 | Investing.com | ||
| 29.06. | Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease | 585 | GlobeNewswire (Europe) | IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy... ► Artikel lesen | |
| 25.06. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Gain Therapeutics, Inc.: Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2 | GlobeNewswire (USA) | ||
| 27.05. | Oppenheimer bestätigt "Outperform" für Gain Therapeutics | 6 | Investing.com Deutsch | ||
| 27.05. | Gain Therapeutics stock maintained at Outperform by Oppenheimer | 3 | Investing.com | ||
| 26.05. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Gain Therapeutics presents phase 1b data on Parkinson's drug | 3 | Investing.com | ||
| 11.05. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,842 | +0,99 % | InflaRx NV-Aktie im Check am 19.09. (11:10 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 5,4 Millionen US-Dollar pro Patient: Warum Medtronic, Globus Medical und NurExone an derselben Verletzung ansetzen | ||
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,368 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,842 | -0,35 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,010 | -2,83 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,020 | +2,03 % | Emergent BioSolutions: Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+0,28 %) liegt der Kurs bei 1,765 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.